Array BioPharma: National Comprehensive Cancer Network, FDA OKs drug combo for melanoma

Array BioPharma: National Comprehensive Cancer Network, FDA OKs drug combo for melanoma

BOULDER -- Array BioPharma Inc. (Nasdaq: ARRY) announced that the National Comprehensive Cancer Network (NCCN) has updated the Clinical Practice Guidelines in Oncology for Melanoma to include... Read More

Monday July 16, 2018 0 comments Tags: Boulder, Array BioPharma, melanoma, Ron Squarer, FDA

Array BioPharma announces FDA approval of encorafenib and binimetinib cancer drugs

Array BioPharma announces FDA approval of encorafenib and binimetinib cancer drugs

BOULDER -- Array BioPharma Inc . (Nasdaq: ARRY) announced the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI(encorafenib) capsules in combination with MEKTOVI(binimetinib)tablets... Read More

Thursday June 28, 2018 0 comments Tags: Boulder, Array BioPharma, encorafenib, binimetinib, Ron Squarer

Array BioPharma reports positive survival results for melanoma drugs

Array BioPharma reports positive survival results for melanoma drugs

BOULDER -- Array BioPharma Inc . (Nasdaq: ARRY) andFrance-based Pierre Fabreannounced results of a study of overall survival in patients with BRAF -mutant melanoma, indicating that treatment with... Read More

Wednesday February 7, 2018 0 comments Tags: Boulder, Array BioPharma, encorafenib, binimetinib, Victor Sandor

Array’s triplet drug combination found effective for colorectal cancer treatment

Array’s triplet drug combination found effective for colorectal cancer treatment

BOULDER -- Array BioPharma Inc. (Nasdaq: ARRY) and Pierre Fabre today announced updated results from the 30 patient safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet... Read More

Monday January 22, 2018 0 comments Tags: Boulder, Array BioPharma, binimetinib, encorafenib, cetuximab, Pierre Fabre

Array BioPharma to collaborate with Pfizer on clinical drug trials

Array BioPharma to collaborate with Pfizer on clinical drug trials

BOULDER -- Array BioPharma (Nasdaq: ARRY) today announced it has entered into a clinical trial collaboration agreement with Pfizer to investigate the safety and efficacy of several novel... Read More

Tuesday December 19, 2017 0 comments Tags: Boulder, Array BioPharma, Pfizer, Ron Squarer

CBSA to honor life science innovators, leaders tonight

CBSA to honor life science innovators, leaders tonight

DENVER -- Colorado BioScience Association (CBSA) will highlight a banner year marked by acquisitions, investments, discoveries and partnerships during its 14 th Annual Awards Dinner tonight in... Read More

Thursday November 9, 2017 0 comments Tags: Denver, CBSA, April Giles, Array BioPharma, miRagen Therapeutics, Sharklet Technologies, Cerescan, Eximis Surgical, Ocugen, Boettcher Foundation

Array BioPharma to raise $225M through stock sale

Array BioPharma to raise $225M through stock sale

BOULDER -- Array BioPharma Inc. (Nasdaq: ARRY) announced the pricing of an underwritten public offering of 20,930,232 shares of its common stock at a public offering price of$10.75per share. ... Read More

Friday September 15, 2017 0 comments Tags: Boulder, Array BioPharma

Array BioPharma announces FDA acceptance to review new melanoma drug applications

Array BioPharma announces FDA acceptance to review new melanoma drug applications

BOULDER -- Array BioPharma (Nasdaq: ARRY) announced the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Applications (NDAs) to support use of the combination of... Read More

Wednesday September 13, 2017 0 comments Tags: Boulder, Array BioPharma, Ron Squarer, encorafenib, binimetinib